Highly Sensitive Lineage Discrimination of SARS-CoV-2 Variants through Allele-Specific Probe PCR
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Tools to detect SARS-CoV-2 variants of concern and track the ongoing evolution of the virus are necessary to support public health efforts and the design and evaluation of novel COVID-19 therapeutics and vaccines. Although next-generation sequencing (NGS) has been adopted as the gold standard method for discriminating SARS-CoV-2 lineages, alternative methods may be required when processing samples with low viral loads or low RNA quality.
Article activity feed
-
-
SciScore for 10.1101/2021.11.01.21265384: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: REMAP-CAP was performed in accordance with regulatory and legal requirements (EudraCT number: 2015-002340-14) and was approved by London-Surrey Borders Research Ethics Committee London Centre (18/LO/0660). Sex as a biological variable not detected. Randomization Sample Collection: The REMAP-CAP Immunological Domain was an international, open-label, randomized convalescent plasma trial enrolling patients aged 18 years or older receiving intensive care-level organ support. Blinding not detected. Power Analysis not detected. Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data …
SciScore for 10.1101/2021.11.01.21265384: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: REMAP-CAP was performed in accordance with regulatory and legal requirements (EudraCT number: 2015-002340-14) and was approved by London-Surrey Borders Research Ethics Committee London Centre (18/LO/0660). Sex as a biological variable not detected. Randomization Sample Collection: The REMAP-CAP Immunological Domain was an international, open-label, randomized convalescent plasma trial enrolling patients aged 18 years or older receiving intensive care-level organ support. Blinding not detected. Power Analysis not detected. Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
Identifier Status Title NCT02735707 Recruiting Randomized, Embedded, Multifactorial Adaptive Platform Trial… NCT04536051 Recruiting A Study of a Candidate COVID-19 Vaccine (COV003) Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- No funding statement was detected.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
